welcome to oneEDSvoice- a positively charged Ehlers Danlos Syndrome community.
- join today!
Markus-Frederik Bohn, Ph.D
Department of Pharmaceutical Chemistry
University of California in San Francisco (UCSF)
San Francisco, California, United States
Markus-Frederik Bohn, PhD contributes to EDS research in the field of Tenascin X, a now more common factor and potential cause in many EDS patients. Markus has published many scientific articles and currently works at University of California in San Francisco (UCSF) in the Department of Pharmaceutical Chemistry. Markus has both a professional interest and a personal interest in Ehlers-Danlos Syndrome via a family member. In addition to EDS, he is currently interested in identifying novel therapeutic targets for antiviral strategies at the host-pathogen interface. He is fluent in both German and English.
Ph.D, University of Massachusetts Medical School
Master’s program in molecular and cellular biology, University of Erlangen-Nuremberg, Germany
expertly curated content related to this topic
Acer Therapeutics and Opexa Therapeutics Sign Merger AgreementOpexa Therapeutics, Inc. (Nasdaq: OPXA) ...
Periodontal Ehlers-Danlos Syndrome Associated with Type III and I Collagen DeficienciesIn 1997, Ehlers-Danlos syndrome type VII...
Ehlers Danlos Syndrome and OsteoporosisEhlers Danlos syndrome (EDS) is a group ...
Steven Freeman, MPT, ATC, CHTSteve Freeman is a certified Hand Therap...
Subinoy Das, MD, FACS, FARSSubinoy Das, MD, FACS, FARS is the Chief...
Myles B. Koby, MDDr. Myles B Koby is a Diagnostic Radiolo...
Delia Chiaramonte, MDDelia Chiaramonte, M.D. is an integrati...